Designed to run seamlessly on the BioCode® MDx-3000 system, this multiplex nucleic acid amplification test delivers unparalleled accuracy in identifying DNA from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), Mycoplasma genitalium (MG), as well as macrolide-resistant and fluoroquinolone-resistant single nucleotide polymorphism (SNP) mutations—all within a single reaction.

The BioCode® STI + Resistance Panel (RUO) is tailored to meet the demands of modern research laboratories, offering rapid results in approximately 4 hours post-DNA extraction. Engineered with precision, the MDx-3000 system boasts intuitive protocol and reporting software, streamlining workflows and accommodating up to 96 samples per test run.

Winston Ho, Founder and Chief Technology Officer at Applied BioCode Inc., expressed his enthusiasm for the launch, stating, "We are thrilled to introduce the STI + Resistance Panel for research use, aligning with our strategic vision to provide laboratories with access to cutting-edge panels. This release and future offerings will empower researchers to gather real-world clinical data while expanding the menu of options on the MDx-3000 platform in the United States."